NEW ORLEANS, June 5, 2017 /PRNewswire/ -- Findings presented at the American Society for Microbiology's ASM Microbe conference
The Sgx Clarity system is CE marked and currently available in the European market.
In initial pilot studies, the Sgx Clarity C. difficile assay demonstrated the ability to detect the disease-causing toxins at concentrations up to 100 times lower than commercially available immunoassay methods. The turnaround time for the Sgx Clarity C. difficile toxin A/B assay was shown to be less than one hour, allowing for rapid detection and rule-out of suspected C. difficile infections (CDI).
"Having an ultra-sensitive C difficile toxin immunoassay would be a game changer," said Christopher Polage, Associate Professor of Pathology and Infectious Diseases, University of California, Davis School of Medicine. "Our experience shows the importance of toxin testing to identify patients with C difficile infection and minimize over-diagnosis but there's still a lot of anxiety in the field. Labs worry about missing individual CDI cases but hospitals are facing huge financial pressures to reduce CDI and blaming labs for using tests that don't distinguish between infected and colonized patients. Having an ultra-sensitive toxin test would allow labs to give physicians a toxin result to help maximize the accuracy of CDI diagnosis without the worry of missing cases. This would improve patient care and allow hospitals to reduce CDI rates and avoid financial penalties, representing a 'win-win' for everyone."
The Single Molecule Counting-based C. difficile toxin A and B assay aims to be the first ultra-sensitive test to offer physicians and laboratorians the specificity intrinsic to toxin tests but at a sensitivity level that rivals molecular methods. The clinical goal is to help clinicians safely to rule out C. difficile infection with greater confidence and provide clinically actionable toxin detection in under an hour.
"What makes our assays so promising is the degree of sensitivity and high precision we are able to offer with our Single Molecule Counting technology," said Dr. Jeff Bishop, Sr. Vice President of Research and Development, who is leading C. difficile assay development at Singulex. "We continue to gain important insights into its use in infectious disease through our work with key opinion leaders in the US and in Europe and are looking forward to the next stage of development."
The Singulex proprietary Single Molecule Counting technology has been validated in clinical studies involving more than 130,000 subjects, resulting in over 130 peer-reviewed publications. The company will submit data this year for regulatory clearance of the Sgx Clarity system in the United States, anticipating U.S. Food and Drug Administration clearance in 2018.
About Clostridium difficile infection C. difficile infection is the leading cause of gastroenteritis-associated death and has become the most common cause of health care–associated infections in U.S. hospitals. The excess health care costs related to C. difficile infection are estimated to be as much as $4.8 billion for acute care facilities alone. According to a study funded by the Centers for Disease Control and Prevention, C. difficile was responsible for almost half a million infections and was associated with approximately 29,000 deaths in 2011.
C. difficile is a bacterium found in the air, water, soil, and in the feces of humans and animals. The bacteria are often spread in hospitals and nursing homes. Older adults in healthcare facilities are at most risk, though an increasing number of younger adults also develop C. difficile infections characterized by diarrhea more than 3 times a day, severe cramping, fever, nausea and dehydration.
About Singulex, Inc.Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, new immunoassay technology recognized for unprecedented ultra-sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Sgx Clarity System, a fully-automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1,000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than possible before. Assays to detect and rule out cardiac, infectious and inflammatory disease are in development. Singulex is also exploring a point of care platform and applications beyond the clinical setting.For more information, please visit www.singulex.com.
REFERENCE Lessa F, Mu Y, Bamberg W, et al, Burden of Clostridium difficile Infection in the United States: N Engl J Med 2015;372:825-34. http://www.nejm.org/doi/pdf/10.1056/NEJMoa1408913 Accessed May 25, 2017
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ultra-sensitive-c-difficile-assay-in-development-by-singulex-demonstrates-potential-to-improve-diagnosis-in-pilot-studies-300468763.html
SOURCE Singulex, Inc.
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All